Mycophenolate mofetil enhances the effects of tacrolimus on the inhibitory function of regulatory T cells in patients after liver transplantation via PD-1 and TIGIT receptors

References

• Glišić TM, Perišić MD, Dimitrijevic S, et al. Doppler assessment of splanchnic arterial flow in patients with liver cirrhosis: correlation with ammonia plasma levels and MELD score. J Clin Ultrasound. 2014;42(5):264–269.
   PubMed Web of Science ®Google Scholar
• Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4 + CD25 + Foxp3+ regulatory T lymphocytes. Nat Med. 2008;14(1):88–92. 12/09/online
   PubMed Web of Science ®Google Scholar
• Sagoo P, Ali N, Garg G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3(83):83ra42.
   PubMed Web of Science ®Google Scholar
• Todo S, Yamashita K, Goto R, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology. 2016;64(2):632–643.
   PubMed Web of Science ®Google Scholar
• Mathew JM, Jessica H, LeFever A, et al. A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants. Sci Rep. 2018;8(1):7428.
   PubMedGoogle Scholar
• Romano M, Fanelli G, Albany CJ, et al. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front Immunol. 2019;10:43.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Yuan XY, Li W, et al. Effects of tacrolimus (FK506) and mycophenolate mofetil (MMF) on regulatory T cells and co-inhibitory receptors in the peripheral blood of human liver allograft patients. Immunopharmacol Immunotoxicol. 2019;41(3):380–385.
   PubMed Web of Science ®Google Scholar
• Scottà C, Fanelli G, Hoong SJ, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. 2016;101(1):91–100.
   PubMed Web of Science ®Google Scholar
• Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19(1):3–26.
   PubMed Web of Science ®Google Scholar
• Bakrac M, Jurisic V, Kostic T, et al. Pure red cell aplasia associated with type I autoimmune polyglandular syndrome—successful response to treatment with mycophenolate mofetil: case report and review of literature. J Clin Pathol. 2007;60(6):717–720.
   PubMed Web of Science ®Google Scholar
• Demirkiran A, Sewgobind VD, van der Weijde J, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4 + FOXP3+ regulatory T cells. Transplantation. 2009;87(7):1062–1068.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4 + CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108(1):390–399.
   PubMed Web of Science ®Google Scholar
• Sojka DK, Fowell DJ. Regulatory T cells inhibit acute IFN-γ synthesis without blocking T-helper cell type 1 (Th1) differentiation via a compartmentalized requirement for IL-10. Proc Natl Acad Sci USA. 2011;108(45):18336–18341.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.
   PubMed Web of Science ®Google Scholar
• Akhmetzyanova I, Drabczyk M, Neff CP, et al. PD-L1 expression on retrovirus-infected cells mediates immune escape from CD8+ T cell killing. PLoS Pathog. 2015;11(10):e1005224.
   PubMed Web of Science ®Google Scholar
• Shrimali RK, Janik JE, Abu-Eid R, et al. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy. 2015;7(7):777–792.
   PubMed Web of Science ®Google Scholar
• Seung E, Dudek TE, Allen TM, et al. PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLoS One. 2013;8(10):e77780.
   PubMed Web of Science ®Google Scholar
• Porichis F, Kwon DS, Zupkosky J, et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011;118(4):965–974.
   PubMed Web of Science ®Google Scholar
• Chihab H, Jadid FZ, Foka P, et al. Programmed cell death-1 3'-untranslated region polymorphism is associated with spontaneous clearance of hepatitis B virus infection. J Med Virol. 2018;90(11):1730–1738.
   PubMed Web of Science ®Google Scholar
• Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018;128(10):4573–4587.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–3175.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 2012/06/28366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Chauvin J-M, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015;125(5):2046–2058.
   PubMed Web of Science ®Google Scholar
• Kurtulus S, Sakuishi K, Ngiow S-F, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125(11):4053–4062.
   PubMed Web of Science ®Google Scholar
• Hung AL, Maxwell R, Theodros D, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. 2018;7(8):e1466769.
   PubMed Web of Science ®Google Scholar
• Yasuma K, Yasunaga J-i, Takemoto K, et al. HTLV-1 bZIP factor impairs anti-viral immunity by inducing co-inhibitory molecule, T cell immunoglobulin and ITIM domain (TIGIT). PLoS Pathog. 2016;12(1):e1005372.
   PubMed Web of Science ®Google Scholar
• Chew GM, Fujita T, Webb GM, et al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLoS Pathog. 2016;12(1):e1005349.
   PubMed Web of Science ®Google Scholar
• Yasuma-Mitobe K, Matsuoka M. The roles of coinhibitory receptors in pathogenesis of human retroviral infections. Front Immunol. 2018;9:2755.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Terzic T, Colic S, et al. The concentration of TNF-alpha correlate with number of inflammatory cells and degree of vascularization in radicular cysts. Oral Dis. 2008;14(7):600–605.
   PubMed Web of Science ®Google Scholar
• Hahn AB, Kasten-Jolly JC, Constantino DM, et al. TNF-alpha, IL-6, IFN-gamma, and IL-10 gene expression polymorphisms and the IL-4 receptor alpha-chain variant Q576R: effects on renal allograft outcome . Transplantation. 2001;72(4):660–665.
   PubMed Web of Science ®Google Scholar
• Tang X, Marciano DL, Leeman SE, et al. LPS induces the interaction of a transcription factor, LPS-induced TNF-alpha factor, and STAT6(B) with effects on multiple cytokines. Proc Natl Acad Sci USA. 2005;102(14):5132–5137.
   PubMed Web of Science ®Google Scholar